Cronos GroupCRON +3.31%86 Net Margin % is 30.42% as of Mar. 2026. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 956 Drug Manufacturers companies, Cronos Group ranks worse than 67.47% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cronos Group's Net Income for the
three
months ended in Mar. 2026 was $13.8 Mil. Cronos Group's Revenue for the
three
months ended in Mar. 2026 was $45.2 Mil. Therefore, Cronos Group's net margin for the quarter that ended in Mar. 2026 was 30.42%.
The historical rank and industry rank for Cronos Group's Net Margin % or its related term are showing as below:
CRON'
s Net Margin % Range Over the Past 10 Years
Min: -613.54 Med: -120.67 Max: 4911.66
Current: -0.91
CRON's Net Margin % is ranked worse than 67.47% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CRON: -0.91
Cronos Group (NAS:CRON) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cronos Group Net Margin % Related Terms
Cronos Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Cronos Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cronos Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a Net Margin % of 30.42% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #645 out of 956 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Cronos Group's Net Margin % too high?
Cronos Group's current Net Margin % is 30.42%. The Drug Manufacturers industry median Net Margin % is 5.56. Cronos Group's value of 30.42% is 447.1% above this industry median. Based on the distribution chart, Cronos Group ranks #645 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #645 out of 956 companies for Net Margin %. This places Cronos Group in the lower half of its industry. The industry median Net Margin % is 5.56. Cronos Group's value of 30.42% is 447.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Net Margin % of 30.42% is 447.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Net Margin % is 30.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.45, compared to a current price of $2.82 — trading 18.3% below its estimated fair value. The current Net Margin % is 30.42% and 447.1% above the Drug Manufacturers industry median of 5.56. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cronos Group (CRON), the current Net Margin % is 30.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.82 is trading 18.3% below its estimated GF Value™ of $3.45.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
Net Margin %: 30.42%
GF Value™: $3.45 vs. price of $2.82 (18.3% below fair value)
Industry Position: 447.1% above the Drug Manufacturers median (#645 of 956)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
